On Friday, Shares of Comcast Corporation (NASDAQ:CMCSK), lost -2.83% to $58.00.
Comcast Corporation declared that at its special meeting of shareholders in Philadelphia, holders of its Class A Common Stock and Class A Special Common Stock, each voting separately as a class, and Class A Common Stock and Class B Common Stock, voting together as a single class, approved the Company’s proposal to amend and restate its Amended and Restated Articles of Incorporation in order to reclassify each share of Comcast Class A Special Common Stock (Nasdaq: CMCSK) into one share of Comcast Class A Common Stock (Nasdaq: CMCSA).
Effective as of 5:00 PM (EST) on December 11, 2015, each share of Comcast’s Class A Special Common Stock will be reclassified into one share of Comcast’s Class A Common Stock, and the Class A Special Common Stock will cease trading on Nasdaq. Comcast’s Class A Common Stock, counting the new shares of Class A Common Stock into which the shares of Class A Special Common Stock were reclassified, will continue to trade on Nasdaq under the ticker symbol CMCSA.
Comcast Corporation operates as a media and technology company worldwide. It operates through Cable Communications, Cable Networks, Broadcast Television, Filmed Entertainment, and Theme Parks segments. The Cable Communications segment offers video, high-speed Internet, and voice services to residential and business customers under the XFINITY brand name.
Shares of Eli Lilly and Co (NYSE:LLY), declined -1.90% to $83.30, during its last trading session.
Eli Lilly and Company (LLY) and Merck (MRK), known as MSD outside the United States and Canada, declared another immuno-oncology partnership Athat will evaluate abemaciclib (LY2835219), Lilly’s cyclin-dependent kinase (CDK) 4 and 6 inhibitor, and Merck’s KEYTRUDA® (pembrolizumab) in a Phase I study across multiple tumor types. Based on the Phase I trial results, the partnership has the potential to progress to Phase II trials in patients who have been diagnosed with either metastatic breast cancer or non-small cell lung cancer (NSCLC).
Lilly is the sponsor of the Phase I study, and of any subsequent Phase II studies, per the terms of the agreement. Enrollment is planned to start in early 2016. Financial details of the partnership were not revealed.
Lilly’s abemaciclib is a cell cycle inhibitor, designed to block the growth of cancer cells by specifically inhibiting CDK4 and CDK6. Pembrolizumab is a humanized monoclonal antibody that works by increasing the ability of the body’s immune system to assist detect and fight tumor cells. Pembrolizumab blocks the interaction between PD-1 and its ligands, PD-L1 and PD-L2, thereby activating T lymphocytes, which may affect both tumor cells and healthy cells.
Eli Lilly and Company discovers, develops, manufactures, and sells pharmaceutical products worldwide. It operates through two segments, Human Pharmaceutical Products and Animal Health Products. The company offers endocrinology products to treat diabetes; osteoporosis in postmenopausal women and men; human growth hormone deficiency and pediatric growth conditions; and testosterone deficiency.
Finally, Southern Co (NYSE:SO), ended its last trade with -0.17% loss, and closed at $44.42.
Georgia Power declared the latest milestone in the expansion of Plant Vogtle near Waynesboro, Georgia – the placement of the lower ring for Unit 4. The 1.9 million-pound lower ring was lifted into place by the heavy lift derrick, one of the largest cranes in the world, and is the first of three containment vessel rings for Unit 4.
“Weighing nearly 1,000 tons, the placement of the lower ring for Unit 4 required a tremendous amount of precision and planning to be accomplished safely and correctly,” said Mark Rauckhorst, vice president of construction for Vogtle 3 &4.
Other recent milestones for the Vogtle expansion comprise the receipt of the last major permit needed for the new units, the National Pollutant Discharge Elimination System permit; the placement of the concrete “turbine tabletop” for Unit 3 and the placement of the 2.28 million-pound Unit 3 CA01 module.
The Southern Company, together with its auxiliaries, operates as a public electric utility company. It is involved in the generation, transmission, and distribution of electricity through coal, nuclear, oil and gas, and hydro resources in the states of Alabama, Georgia, Florida, and Mississippi.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified with such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.